Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2016

04.04.2016 | Review

Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children

verfasst von: Jonathan A. Africa, Kimberly P. Newton, Jeffrey B. Schwimmer

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease among children. Lifestyle interventions, such as diet and exercise, are frequently recommended. Children with NAFLD have a distinct physiology that is different from obesity alone and has the potential to influence lifestyle treatments. Studies of diet alone in the treatment of pediatric NAFLD have focused on sugar and carbohydrate, but did not indicate any one dietary approach that was superior to another. For children who are obese and have NAFLD, weight loss may have a beneficial effect regardless of the diet used. Exercise is widely believed to improve NAFLD because a sedentary lifestyle, poor aerobic fitness, and low muscle mass are all risk factors for NAFLD. However, there have been no randomized controlled trials of exercise as a treatment for children with NAFLD. Studies of the combination of diet and exercise suggest a potential for improvement in serum alanine aminotransferase activity and/or magnetic resonance imaging liver fat fraction with intervention. There is also enthusiasm for the use of dietary supplements; however, studies in children have shown inconsistent effects of vitamin E, fish oil, and probiotics. This review presents the available data from studies of lifestyle intervention and dietary supplements published to date and highlights challenges that must be addressed in order to advance the evidence base for the treatment of pediatric NAFLD.
Literatur
1.
Zurück zum Zitat Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–1393.CrossRefPubMed Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–1393.CrossRefPubMed
2.
Zurück zum Zitat Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, et al., Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr. 2014;164:707–713.e3. Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, et al., Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr. 2014;164:707–713.e3.
3.
Zurück zum Zitat Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538–1544.CrossRefPubMedPubMedCentral Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538–1544.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Nobili V, Alisi A, Grimaldi C, et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes. 2014;9:e99–e102.CrossRefPubMed Nobili V, Alisi A, Grimaldi C, et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes. 2014;9:e99–e102.CrossRefPubMed
5.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.CrossRefPubMed
6.
Zurück zum Zitat Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart association pediatric and adult nutrition guidelines: a scientific statement from the american heart association nutrition committee of the council on nutrition, physical activity and metabolism. Counc Cardiovasc Dis Circul. 2009;119:1161–1175. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart association pediatric and adult nutrition guidelines: a scientific statement from the american heart association nutrition committee of the council on nutrition, physical activity and metabolism. Counc Cardiovasc Dis Circul. 2009;119:1161–1175.
7.
Zurück zum Zitat Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128;S213–S256.CrossRefPubMedCentral Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128;S213–S256.CrossRefPubMedCentral
8.
Zurück zum Zitat Schwimmer JB, Newton KP, Awai HI, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:1267–1277.CrossRefPubMedPubMedCentral Schwimmer JB, Newton KP, Awai HI, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:1267–1277.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol. 2014;12:765–773.CrossRefPubMedPubMedCentral Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol. 2014;12:765–773.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015;n/a–n/a. Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015;n/a–n/a.
11.
Zurück zum Zitat Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013;9:252–260.PubMedPubMedCentral Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013;9:252–260.PubMedPubMedCentral
12.
Zurück zum Zitat Jin R, Welsh JA, Le N-A, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6:3187–3201.CrossRefPubMedPubMedCentral Jin R, Welsh JA, Le N-A, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6:3187–3201.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283.CrossRefPubMedPubMedCentral Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105–1112.CrossRefPubMed Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105–1112.CrossRefPubMed
16.
Zurück zum Zitat Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology. 2013;58:1287–1295.CrossRefPubMed Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology. 2013;58:1287–1295.CrossRefPubMed
17.
Zurück zum Zitat Bacchi E, Negri C, Zanolin ME, et al. Metabolic effects of aerobic training and resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2 study). Diabetes Care. 2012;35:676–682.CrossRefPubMedPubMedCentral Bacchi E, Negri C, Zanolin ME, et al. Metabolic effects of aerobic training and resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2 study). Diabetes Care. 2012;35:676–682.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Lee S, Deldin AR, White D, et al. Aerobic exercise but not resistance exercise reduces intrahepatic lipid content and visceral fat and improves insulin sensitivity in obese adolescent girls: a randomized controlled trial. Am J Physiol Endocrinol Metab. 2013;305:E1222–E1229.CrossRefPubMedPubMedCentral Lee S, Deldin AR, White D, et al. Aerobic exercise but not resistance exercise reduces intrahepatic lipid content and visceral fat and improves insulin sensitivity in obese adolescent girls: a randomized controlled trial. Am J Physiol Endocrinol Metab. 2013;305:E1222–E1229.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes. 2012;61:2787–2795.CrossRefPubMedPubMedCentral Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes. 2012;61:2787–2795.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat van der Heijden G-J, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring). 2010;18:384–390.CrossRefPubMed van der Heijden G-J, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring). 2010;18:384–390.CrossRefPubMed
21.
Zurück zum Zitat van der Heijden G-J, Wang ZJ, Chu Z, et al. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sport Exerc. 2010;42:1973–1980.CrossRef van der Heijden G-J, Wang ZJ, Chu Z, et al. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sport Exerc. 2010;42:1973–1980.CrossRef
22.
Zurück zum Zitat Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr. 1994;125:239–241.CrossRefPubMed Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr. 1994;125:239–241.CrossRefPubMed
23.
Zurück zum Zitat Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458–465.CrossRefPubMed Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458–465.CrossRefPubMed
24.
Zurück zum Zitat Koot BGP, van der Baan-Slootweg OH, Vinke S, Bohte AE, Tamminga-Smeulders CLJ, Jansen PLM, et al., Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int. J. Obes. 2015;1–33. Koot BGP, van der Baan-Slootweg OH, Vinke S, Bohte AE, Tamminga-Smeulders CLJ, Jansen PLM, et al., Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int. J. Obes. 2015;1–33.
25.
Zurück zum Zitat Pozzato C, Verduci E, Scaglioni S, et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. J Pediatr Gastroenterol Nutr. 2010;51:1.CrossRef Pozzato C, Verduci E, Scaglioni S, et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. J Pediatr Gastroenterol Nutr. 2010;51:1.CrossRef
27.
Zurück zum Zitat DeVore S, Kohli R, Lake K, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013;57:119–123.CrossRefPubMedPubMedCentral DeVore S, Kohli R, Lake K, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013;57:119–123.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Effect of weight reduction on serum transaminase activities in children with simple obesity. J Pediatr. 1996;128:587–588.CrossRefPubMed Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Effect of weight reduction on serum transaminase activities in children with simple obesity. J Pediatr. 1996;128:587–588.CrossRefPubMed
29.
Zurück zum Zitat Grønbæk H, Lange A, Birkebæk NH, et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr. 2012;54:223–228.CrossRefPubMed Grønbæk H, Lange A, Birkebæk NH, et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr. 2012;54:223–228.CrossRefPubMed
30.
Zurück zum Zitat Campos RMS, De Piano A, Da Silva PL, et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine. 2012;42:146–156.CrossRefPubMed Campos RMS, De Piano A, Da Silva PL, et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine. 2012;42:146–156.CrossRefPubMed
31.
Zurück zum Zitat Pacifico L, Arca M, Anania C, Cantisani V, Di Martino M, Chiesa C. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2013;23:1010–1016.CrossRefPubMed Pacifico L, Arca M, Anania C, Cantisani V, Di Martino M, Chiesa C. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2013;23:1010–1016.CrossRefPubMed
32.
Zurück zum Zitat Sanches PL, de Piano A, Campos RMS, et al. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. J Clin Lipidol. 2014;8:265–272.CrossRefPubMed Sanches PL, de Piano A, Campos RMS, et al. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. J Clin Lipidol. 2014;8:265–272.CrossRefPubMed
34.
Zurück zum Zitat Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734–738.CrossRefPubMed Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734–738.CrossRefPubMed
35.
Zurück zum Zitat Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–1668.CrossRefPubMedPubMedCentral Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–1668.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–1561.CrossRefPubMed Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–1561.CrossRefPubMed
37.
Zurück zum Zitat Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48–55.CrossRefPubMed Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48–55.CrossRefPubMed
38.
Zurück zum Zitat Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350–353.CrossRefPubMed Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350–353.CrossRefPubMed
39.
Zurück zum Zitat Nobili V, Carpino G, Alisi A, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One. 2014;9:e88005.CrossRefPubMedPubMedCentral Nobili V, Carpino G, Alisi A, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One. 2014;9:e88005.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25:734–741.CrossRefPubMed Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25:734–741.CrossRefPubMed
41.
Zurück zum Zitat Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al., Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166:1358–1363.e3. Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al., Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166:1358–1363.e3.
42.
Zurück zum Zitat Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740–743.CrossRefPubMed Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740–743.CrossRefPubMed
43.
Zurück zum Zitat Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–1285.CrossRefPubMedPubMedCentral Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–1285.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Schwimmer JB. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis. 2007;27:312–318.CrossRefPubMed Schwimmer JB. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis. 2007;27:312–318.CrossRefPubMed
45.
Zurück zum Zitat Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641–649.CrossRefPubMed Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641–649.CrossRefPubMed
46.
47.
Zurück zum Zitat O’sullivan TA, Oddy WH, Bremner AP, et al. Lower fructose intake may help protect against development of nonalcoholic Fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr. 2014;58:624–631.CrossRefPubMed O’sullivan TA, Oddy WH, Bremner AP, et al. Lower fructose intake may help protect against development of nonalcoholic Fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr. 2014;58:624–631.CrossRefPubMed
48.
Zurück zum Zitat Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971.CrossRefPubMedPubMedCentral Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Trilk JL, Ortaglia A, Blair SN, Bottai M, Church TS, Pate RR. Cardiorespiratory fitness, waist circumference, and alanine aminotransferase in youth. Med Sci Sports Exerc. 2013;45:722–727.CrossRefPubMedPubMedCentral Trilk JL, Ortaglia A, Blair SN, Bottai M, Church TS, Pate RR. Cardiorespiratory fitness, waist circumference, and alanine aminotransferase in youth. Med Sci Sports Exerc. 2013;45:722–727.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Gerber L, Otgonsuren M, Mishra A, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012;36:772–781.CrossRefPubMed Gerber L, Otgonsuren M, Mishra A, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012;36:772–781.CrossRefPubMed
51.
Zurück zum Zitat Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology. 2008;48:1791–1798.CrossRefPubMed Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology. 2008;48:1791–1798.CrossRefPubMed
52.
Zurück zum Zitat Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. 2007;104:12587–12594.CrossRefPubMedPubMedCentral Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. 2007;104:12587–12594.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Wittmeier KDM, Wicklow BA, MacIntosh AC, et al. Hepatic steatosis and low cardiorespiratory fitness in youth with type 2 diabetes. Obesity. 2012;20:1034–1040.CrossRefPubMed Wittmeier KDM, Wicklow BA, MacIntosh AC, et al. Hepatic steatosis and low cardiorespiratory fitness in youth with type 2 diabetes. Obesity. 2012;20:1034–1040.CrossRefPubMed
54.
Zurück zum Zitat Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA. 2009;106:8665–8670.CrossRefPubMedPubMedCentral Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA. 2009;106:8665–8670.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA J Am Med Assoc. 2005;293:1338–1347.CrossRef Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA J Am Med Assoc. 2005;293:1338–1347.CrossRef
56.
Zurück zum Zitat Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E cancer prevention trial (SELECT). JAMA. 2011;306:1549–1556.CrossRefPubMedPubMedCentral Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E cancer prevention trial (SELECT). JAMA. 2011;306:1549–1556.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.CrossRefPubMed Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.CrossRefPubMed
59.
Zurück zum Zitat Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024–1033.CrossRefPubMed Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024–1033.CrossRefPubMed
60.
Zurück zum Zitat Bosch J, Gerstein HC, Dagenais GR, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–318.CrossRefPubMed Bosch J, Gerstein HC, Dagenais GR, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–318.CrossRefPubMed
61.
Zurück zum Zitat Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M., No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 triaL. Gastroenterology. 2014;147:377–384.e1. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M., No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 triaL. Gastroenterology. 2014;147:377–384.e1.
62.
Zurück zum Zitat Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind Randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;00:1–8. Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind Randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;00:1–8.
63.
Zurück zum Zitat Degnan FH. Clinical studies involving probiotics: when FDA’s investigational new drug rubric applies-and when it may not. Gut Microbes. 2012;3:485–489.CrossRefPubMedPubMedCentral Degnan FH. Clinical studies involving probiotics: when FDA’s investigational new drug rubric applies-and when it may not. Gut Microbes. 2012;3:485–489.CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg. 2009;18:144–151.CrossRefPubMedPubMedCentral Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg. 2009;18:144–151.CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277–283.CrossRefPubMedPubMedCentral Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277–283.CrossRefPubMedPubMedCentral
66.
Zurück zum Zitat Schwimmer JB, Zepeda A, Newton KP, et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One. 2014;9:e112569.CrossRefPubMedPubMedCentral Schwimmer JB, Zepeda A, Newton KP, et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One. 2014;9:e112569.CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Sert A, Pirgon O, Aypar E, Yilmaz H, Odabas D. Relationship between left ventricular mass and carotid intima media thickness in obese adolescents with non-alcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2012;25:927–934.CrossRefPubMed Sert A, Pirgon O, Aypar E, Yilmaz H, Odabas D. Relationship between left ventricular mass and carotid intima media thickness in obese adolescents with non-alcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2012;25:927–934.CrossRefPubMed
68.
Zurück zum Zitat Alp H, Eklioğlu BS, Atabek ME, et al. Evaluation of epicardial adipose tissue, carotid intima-media thickness and ventricular functions in obese children and adolescents. J Pediatr Endocrinol Metab. 2014;25:927–934. Alp H, Eklioğlu BS, Atabek ME, et al. Evaluation of epicardial adipose tissue, carotid intima-media thickness and ventricular functions in obese children and adolescents. J Pediatr Endocrinol Metab. 2014;25:927–934.
69.
Zurück zum Zitat Singh GK, Vitola BE, Holland MR, Sekarski T, Patterson BW, Magkos F, et al., Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. 2013;162:1160–8, 1168.e1. Singh GK, Vitola BE, Holland MR, Sekarski T, Patterson BW, Magkos F, et al., Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. 2013;162:1160–8, 1168.e1.
70.
Zurück zum Zitat Pacifico L, Di Martino M, De Merulis A, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology. 2014;59:461–470.CrossRefPubMed Pacifico L, Di Martino M, De Merulis A, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology. 2014;59:461–470.CrossRefPubMed
71.
Zurück zum Zitat Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB. Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:396–406.CrossRefPubMedPubMedCentral Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB. Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:396–406.CrossRefPubMedPubMedCentral
Metadaten
Titel
Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children
verfasst von
Jonathan A. Africa
Kimberly P. Newton
Jeffrey B. Schwimmer
Publikationsdatum
04.04.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4126-1

Weitere Artikel der Ausgabe 5/2016

Digestive Diseases and Sciences 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.